Grantham, Mayo, Van Otterloo & Co (GMO)
RCUS icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Arcus Biosciences RCUS Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-35,300
Closed -$605K – 871
2020
Q3 		$605K Sell
35,300
-45,400
-56% -$1.01M ﹤0.01% 602
2020
Q2 		$2M Buy
+80,700
New +$2.18M 0.01% 418

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s RCUS Position: Q4 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Arcus Biosciences (RCUS) in Q4 2020, closing a stake of 35,300 shares — an estimated $605K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in RCUS in Q2 2020 and held it in 2 quarters. The position peaked at $2M in Q2 2020. 148 funds tracked by Wall St. Rank hold RCUS as of Q4 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Arcus Biosciences position as of Q4 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 35,300 Arcus Biosciences shares in Q4 2020, an estimated $605K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Arcus Biosciences in Q2 2020 and held it in 2 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Arcus Biosciences position peaked at $2M in Q2 2020.
  • 148 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2020, filed 12 Feb 2021.